KeywordsPrimary progressive aphasia · Dementia · Brain 18 fluoro-deoxy-glucose positron emission neuroimaging Abstract Background: A primary progressive aphasia (PPA) diagnosis is generally based on clinical criteria, but often symptoms and signs may overlap in the different forms. Recent data have evidenced that brain 18 fluoro-deoxy-glucose positron emission tomography ( 18 F-FDG PET) could support the clinical diagnosis, since specific metabolic patterns are described for the different variants. Aims: We further evaluated the usefulness of 18 F-FDG PET, by both visual qualitative (QL) and quantitative (QN) methods in the initial diagnosis of PPA, focusing on the classification of different variants. Moreover, we also analyzed the role of 18 F-FDG PET in clarifying the association of PPA with the early phase of Alzheimer's disease (AD) or frontotemporal (FTD) dementias. Methods: We consecutively enrolled 35 patients with clinical symptoms of aphasia, suspect of or attributable to PPA. Patients were classified into two groups: 18 cases with clinical symptoms of aphasia but normal neuropsychological tests and an unclear classification of a specific PPA variant (group A) and 17 cases with clinical and neuropsychological signs attributable to PPA with an uncertain differential diagnosis between AD and FTD (group B). All patients underwent brain 18 F-FDG PET/CT, and images were evaluated both by QL and QN, the latter applying an automated analysis program that produced brain regional metabolic maps and normal age-matched control group comparative analysis (z score). Results: 18 F-FDG PET showed different patterns of bilateral cortical hypometabo-lism in the two groups. The combined use of QL and QN permitted to achieved a correct PPA variant diagnosis in 8 of 18 (44.4%) cases of group A and in 14 of 17 (82.3%) of group B, while only QN could support the correct classification of PPA variants in 10 of 18 (55.6%) cases of group A and in 3 of 17 (17.7%) cases of group B in whom the procedure better localized the hypometabolic areas. Conclusions: Brain 18 F-FDG PET had an elevated performance in the early diagnosis of PPA variants and in the advanced PPA AD/FTD classification. QL clarified the development of AD or FTD in advanced PPA cases and supported the differential diagnosis of a PPA variant in a few early cases. QN 18 F-FDG PET evaluation better contributed to the early diagnosis of an unclear metabolic pattern. To correctly identify all cases, patients with diffuse cortical hypometabolism were also included. Larger series are necessary to confirm these data.A total of 35 consecutive patients (15 males, 20 females, aged 53-80 years, mean ± SD value: 69 ± 6.0) with clinical symptoms of aphasia, suspect of or attributable to PPA, were enrolled retrospectively. All patients were investigated for neurological familiar diseases, neurological non-PPA affections, and generally related diseases (hypertension and diabetes mellitus). Laboratory analyses excluded secondary cognitive disorders.Neurological examinations, basal...